AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Daily Turnover | The turnover of GSK on 7/31 was $302.07 Million, Ranking 477
ByAinvest
Thursday, Jul 31, 2025 6:20 pm ET1min read
The turnover of GSK on 7/31/2025 was $302.07 million, ranking 477 in today's market, the Volume is 8.01 million.
GSK(GSK) shares closed at $37.15, down 4.67% on 7/31/2025, down 2.83% in the last 5 trading days, down 3.26% this month, up 9.85% year-to-date and down 6.28% in the last 52 weeks.
*If the company has been listed for less than 52 weeks, the 52-week gain is the gain since the listing.
(The same applies for less than 1 month, or less than 5 trading days)
【History Turnover】
| Date | Turnover | Volume | Price | Performance |
|---|---|---|---|---|
| 7/31/2025 | $302.07 million | 8.01 million | $37.15 | -4.67% |
| 7/30/2025 | $305.14 million | 7.85 million | $38.97 | 3.45% |
| 7/29/2025 | $238.53 million | 6.34 million | $37.67 | 0.59% |
| 7/28/2025 | $140.42 million | 3.73 million | $37.45 | -1.37% |
| 7/25/2025 | $151.75 million | 4.02 million | $37.97 | -0.68% |
【Company Profile】
Gsk Plc was incorporated as an English public limited company on December 6, 1999.The company was formed by a merger between Glaxo Wellcome plc and SmithKline Beecham plc. GSK acquired these two English companies on 27 December 2000 as part of the merger arrangements.GlaxoSmithKline plc is one of the world's leading research-based pharmaceutical and healthcare companies. Headquartered in the UK,the company is a global organisation with offices in over 100 countries and major research centres in the UK, USA, Belgium and China.At the core of the business model is the use of knowledge and development of intellectual property. It creates value by researching, manufacturing and making available products that improve people's health and well-being.The company aims to develop new products that offer significant improvements over existing treatment options and therefore provide value to patients and those who pay for them such as governments, insurers or other third parties.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet